David Smith, MD
Medical Oncology · Ann Arbor, MINPI 1184700056
Payments from drug & device makers
Across 304 payments — averaging $3474.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$474K
- Medivation LLC.$234K
- Genentech, Inc.$124K
- Seagen Inc.$100K
- Pfizer$40K
- Merck$22K
- plus $62K from 10 others
Across 3 payments — averaging $1079.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$2K
- Bristol Myers Squibb$886
- Astellas Pharma Global Development$853
What the payments were for
- Speaking & faculty fees$1,08889%
- Food & beverage$12110%
- Education$121%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 192 | $474,209 |
| Medivation LLC. | 5 | $233,880 |
| Genentech, Inc. | 18 | $124,209 |
| Seagen Inc. | 7 | $99,845 |
| Pfizer | 61 | $40,324 |
| Merck | 3 | $21,623 |
| E.r. Squibb & Sons, L.L.C. | 3 | $17,915 |
| Astellas Pharma Global Development | 5 | $16,220 |
| AstraZeneca | 2 | $15,581 |
| Novartis | 1 | $7,638 |
| Eli Lilly | 1 | $4,451 |
| Regeneron | 1 | $372 |
| Sanofi | 2 | $49 |
| Karyopharm Therapeutics Inc. | 1 | $27 |
| Azurity Pharmaceuticals, Inc. | 1 | $23 |
| Gilead | 1 | $12 |
How this compares
$1,056,378 in reported general payments places this provider in the 75th percentile of 170 medical oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 31 | $421,771 |
| NubeqaDarolutamide | 15 | $158,799 |
| Abiraterone Acetate | 182 | $130,137 |
| OrgovyxRelugolix | 22 | $55,913 |
| Hydrocortisone | 19 | $820 |
| Prednisone | 119 | $702 |
| Bicalutamide | 11 | $382 |
| Levothyroxine Sodium | 20 | $232 |
| Dexamethasone | 13 | $156 |
| Omeprazole | 11 | $86 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Ann Arbor
- Moshe TalpazAnn Arbor$13.7M
- Zachery ReichertAnn Arbor$10.6M
- Paul SwiecickiAnn Arbor$7.6M
- Rashmi ChughAnn Arbor$7M
- John KraussAnn Arbor$6.2M
- Vaibhav SahaiAnn Arbor$5.4M
- Francis WordenAnn Arbor$4.2M
- Harry ErbaAnn Arbor$4.1M
- Angel QinAnn Arbor$3.3M
- Maha HussainAnn Arbor$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.